LabGenius Therapeutics
@labgeni_us
Followers
3K
Following
863
Statuses
797
Combining human and machine intelligence to discover the next generation of therapeutic antibodies.
London, UK
Joined October 2012
EXCITING NEWS! 📣 Today we announce LabGenius’ £35 million Series B fundraise! 🎉🚀 With these funds, we’ll be accelerating the development of both our ML-driven drug discovery platform and therapeutic pipeline of multispecific antibodies 🔬 🗞️ For more details on the round, check out the press release here - 💡Our CEO, @jejfield, shares his personal perspective on what this financing means for LabGenius here -
1
5
15
We’re excited to announce that Dr. Hannah Seitz has joined the LabGenius Team as Chief Business Officer. Hannah, who was previously Evotec’s VP Global Business Development, will lead LabGenius’ business development activities. “We’re delighted that Hannah has joined the team,” said Dr. James Field, CEO of LabGenius. “Her extensive experience in sourcing and executing deals, combined with our proven ability to discover high-performing molecules with non-intuitive designs, will be instrumental in the success of our partnerships.” Read more about the appointment here:
0
0
1
Attending The BioLogic Summit next week? Join our Head of Data Science and Machine Learning, Dr. Winston Haynes, for his presentation describing how LabGenius’ unique discovery platform is being used to establish a wholly-owned pipeline of highly selective T-cell engagers for the treatment of solid tumours. LabGenius’ platform, which is underpinned by the closed-loop integration of ML and high-throughput experimentation, is enabling the company to pursue targets that have traditionally been associated with on-target, off-tumour toxicity. Find out more here:
0
0
1
Did you miss our presentation at #PEGSEurope? Watch the video below to hear James Field describe how LabGenius' unique discovery platform is being used to establish a wholly-owned pipeline of highly selective T-cell engagers for the treatment of solid tumours. LabGenius’ platform, which is underpinned by the closed-loop integration of ML and high-throughput experimentation, is enabling the company to pursue targets that have traditionally been associated with on-target off-tumour toxicity. Interested in learning more? Get in touch via: partnerships@labgeni.us
0
0
1
Are you attending #PEGSEurope? Join our CEO, James Field, as he describes how LabGenius’ unique discovery platform is being used to establish a wholly-owned pipeline of highly selective T-cell engagers for the treatment of solid tumours. LabGenius’ platform, which is underpinned by the closed-loop integration of ML and high-throughput experimentation, is enabling the company to pursue targets that have traditionally been associated with on-target off-tumour toxicity. 📅 Wednesday, 6 November 2024 ⏰ 12:15 pm 📍#PEGSEurope, Spain
0
1
3
RT @SynbiCITE: We're pleased to announce that James Field, CEO of LabGenius will be speaking at SynbiTECH 2024! Secure your ticket now: ht…
0
1
0
RT @MCHammer: Congratulations @jejfield and the @labgeni_us team !!! Accelerate 🚀🚀🚀 London to the Bay !!! #Hamm400✨✍🏽
0
4
0
0
3
0
RT @BiotechTVHQ: From London: @jejfield describes how @labgeni_us is using machine intelligence to design the next generation of multispeci…
0
2
0
RT @jusjosgra: Our review paper on designing VHH-based bispecific antibodies and relevant machine learning applications
0
1
0
🚀 We're looking forward to the 20th annual @PEGSboston summit. Join Dr Winston Haynes @hayneswa, Head of Data Science & Machine Learning, on Tuesday 14th May at 12pm for his talk on the role of machine learning in overcoming challenges in antibody discovery. 📈 Discover how LabGenius applies an iterative active learning method to enable co-optimisation of antibodies across multiple properties. Learn how this approach delivers highly potent and efficacious immune cell engagers with best-in-class killing selectivity. If you'd like to meet our team in Boston, get in touch at partnerships@labgeni.us To register visit: #immunooncology #drugdiscovery #antibodies #PEGS
0
0
2
RT @KathyYWei1: Come chat with Elise de Reus (@cradlebio), James Field (@labgeni_us ), Maya Skubatch (@wilsonsonsini ), and myself (@310ai_…
0
2
0
We're looking forward to connecting with prospective partners at #LSXWorldCongress in London April 29-30. Meet with James Field, CEO & Founder @jejfield, and Tonya Frolov (BD) to explore the discovery of next generation therapeutic antibodies across a range of application areas. Email us at partnerships@labgeni.us to schedule a meeting, or head over to the portal: To register: #drugdiscovery #proteintherapeutics
0
1
3
RT @RecursionPharma: Earlier today, we hosted a mixer to celebrate our #London office announcement with some key members and brightest mind…
0
7
0
Attending @OBN_UK #BioTrinity 2024? Be sure to catch James Field, @jejfield CEO & Founder, who will be presenting as part of the 'Oncology R&D Spotlight' session on Wednesday, April 24th, from 09:30 to 10:45. And if you'd like to meet with James to learn about our ML-driven protein engineering platform for the discovery of high performing therapeutics, please email us at partnerships@labgeni.us, send us a DM, or schedule a meeting here: 📅 23-24 April 2024 📍 Convene, 133 Houndsditch, London 👉
0
1
6
RT @obviousvc: Sometimes, the cure is worse than the disease. Chemotherapy takes a nuclear approach, obliterating healthy cells along with…
0
2
0
0
1
0
RT @labgeni_us: @ruskin147 @ruskin147 great morning today! Looking sharp in a lab coat with @jejfield 😎
0
3
0
0
3
11